Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2001 May;70(5):624–630. doi: 10.1136/jnnp.70.5.624

Both total and phosphorylated tau are increased in Alzheimer's disease

M Sjogren 1, P Davidsson 1, M Tullberg 1, L Minthon 1, A Wallin 1, C Wikkelso 1, A Granerus 1, H Vanderstichele 1, E Vanmechelen 1, K Blennow 1
PMCID: PMC1737352  PMID: 11309456

Abstract

BACKROUND—Pathological tau protein concentrations in CSF are found in both Alzheimer's disease (AD) and frontotemporal dementia (FTD), but studies on brain tissue have suggested that the tau pathology in AD differs from that in FTD and that the difference may be related to the degree of phosphorylation. As CSF tau protein is increased after stroke, tau may also be implicated in the pathophysiology of vascular dementia, of which subcortical arteriosclerotic encephalopathy (SAE) is a putative subtype.
OBJECTIVES—To investigate the nature of tau protein in CSF and the involvement of total CSF tau and phosphorylated CSF tau (phosphotau) in various types of dementia.
METHODS—Using ELISAs for total tau and tau phosphorylated at Thr181 (phosphotau), the CSF concentrations of total tau and phosphotau were determined in patients with probable and possible AD (n=41 and 19, respectively), FTD (n=18), SAE (n=17), and Parkinson's disease (PD; n=15) and in age matched controls (n=17). All the antibodies stained the lower molecular weight bands, whereas only the antibodies that recognise phosphorylated tau stained the higher molecular bands.
RESULTS—Both CSF tau and CSF phosphotau were increased in probable AD compared with FTD (p<0.001), SAE (p<0.001), PD (p<0.001), and controls (p<0.001). CSF phosphotau was increased in possible AD compared with FTD (p<0.001) and SAE (p<0.001). CSF tau and CSF phosphotau were positively correlated in all the groups. Molecular weight forms of tau ranging from 25 kDa to 80 kDa were found in the CSF
CONCLUSION—Both phosphorylated and unphosphorylated tau isoforms were present in the CSF, and tau protein appeared in both truncated and full length forms. The results suggest that the CSF concentrations of tau and phosphotau are increased in about two thirds of patients with probable AD and in half of those with possible AD but are normal in FTD, SAE, and PD compared with normal aging. Values in the normal range do not exclude AD.



Full Text

The Full Text of this article is available as a PDF (186.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., Räihä I., Sourander L., Winblad B., Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):298–305. doi: 10.1136/jnnp.64.3.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C. M., Miura M., Machida N., Lee V. M., Trojanowski J. Q., Sasaki H. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997 Jul 18;236(2):262–264. doi: 10.1006/bbrc.1997.6908. [DOI] [PubMed] [Google Scholar]
  3. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Machida N., Seiki H., Takase S., Clark C. M., Lee V. M. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995 Oct;38(4):649–652. doi: 10.1002/ana.410380414. [DOI] [PubMed] [Google Scholar]
  4. Bennett D. A., Wilson R. S., Gilley D. W., Fox J. H. Clinical diagnosis of Binswanger's disease. J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):961–965. doi: 10.1136/jnnp.53.11.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bissette G., Smith W. H., Dole K. C., Crain B., Ghanbari H., Miller B., Nemeroff C. B. Alterations in Alzheimer's disease-associated protein in Alzheimer's disease frontal and temporal cortex. Arch Gen Psychiatry. 1991 Nov;48(11):1009–1012. doi: 10.1001/archpsyc.1991.01810350049007. [DOI] [PubMed] [Google Scholar]
  6. Blennow K., Fredman P., Wallin A., Gottfries C. G., Långström G., Svennerholm L. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol. 1993;33(2):126–128. doi: 10.1159/000116918. [DOI] [PubMed] [Google Scholar]
  7. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995 Dec;26(3):231–245. doi: 10.1007/BF02815140. [DOI] [PubMed] [Google Scholar]
  8. Bramblett G. T., Trojanowski J. Q., Lee V. M. Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). Lab Invest. 1992 Feb;66(2):212–222. [PubMed] [Google Scholar]
  9. Davidsson P., Puchades M., Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis. 1999 Mar;20(3):431–437. doi: 10.1002/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  10. Davidsson P., Westman A., Puchades M., Nilsson C. L., Blennow K. Characterization of proteins from human cerebrospinal fluid by a combination of preparative two-dimensional liquid-phase electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem. 1999 Feb 1;71(3):642–647. doi: 10.1021/ac980672w. [DOI] [PubMed] [Google Scholar]
  11. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  12. Galasko D., Chang L., Motter R., Clark C. M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998 Jul;55(7):937–945. doi: 10.1001/archneur.55.7.937. [DOI] [PubMed] [Google Scholar]
  13. Goedert M., Jakes R., Crowther R. A., Cohen P., Vanmechelen E., Vandermeeren M., Cras P. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J. 1994 Aug 1;301(Pt 3):871–877. doi: 10.1042/bj3010871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Goedert M., Jakes R., Crowther R. A., Six J., Lübke U., Vandermeeren M., Cras P., Trojanowski J. Q., Lee V. M. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5066–5070. doi: 10.1073/pnas.90.11.5066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goedert M., Jakes R., Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995 Apr 21;189(3):167–169. doi: 10.1016/0304-3940(95)11484-e. [DOI] [PubMed] [Google Scholar]
  16. Goedert M., Wischik C. M., Crowther R. A., Walker J. E., Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988 Jun;85(11):4051–4055. doi: 10.1073/pnas.85.11.4051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Green A. J., Harvey R. J., Thompson E. J., Rossor M. N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett. 1999 Jan 8;259(2):133–135. doi: 10.1016/s0304-3940(98)00904-5. [DOI] [PubMed] [Google Scholar]
  18. Harrington C. R., Mukaetova-Ladinska E. B., Hills R., Edwards P. C., Montejo de Garcini E., Novak M., Wischik C. M. Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5842–5846. doi: 10.1073/pnas.88.13.5842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Harrington C. R., Perry R. H., Perry E. K., Hurt J., McKeith I. G., Roth M., Wischik C. M. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia. 1994 Sep-Oct;5(5):215–228. doi: 10.1159/000106727. [DOI] [PubMed] [Google Scholar]
  20. Hutton M., Lendon C. L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998 Jun 18;393(6686):702–705. doi: 10.1038/31508. [DOI] [PubMed] [Google Scholar]
  21. Ishiguro K., Ohno H., Arai H., Yamaguchi H., Urakami K., Park J. M., Sato K., Kohno H., Imahori K. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett. 1999 Jul 30;270(2):91–94. doi: 10.1016/s0304-3940(99)00476-0. [DOI] [PubMed] [Google Scholar]
  22. Jensen M., Basun H., Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett. 1995 Feb 17;186(2-3):189–191. doi: 10.1016/0304-3940(95)11297-a. [DOI] [PubMed] [Google Scholar]
  23. Johnson G. V., Seubert P., Cox T. M., Motter R., Brown J. P., Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem. 1997 Jan;68(1):430–433. doi: 10.1046/j.1471-4159.1997.68010430.x. [DOI] [PubMed] [Google Scholar]
  24. Kane J. W., Gowland E. A method for the identification of apolipoprotein E isoforms employing chemical precipitation and flat bed isoelectric focusing in agarose. Ann Clin Biochem. 1986 Sep;23(Pt 5):509–513. doi: 10.1177/000456328602300504. [DOI] [PubMed] [Google Scholar]
  25. Khatoon S., Grundke-Iqbal I., Iqbal K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem. 1992 Aug;59(2):750–753. doi: 10.1111/j.1471-4159.1992.tb09432.x. [DOI] [PubMed] [Google Scholar]
  26. Leary J. J., Brigati D. J., Ward D. C. Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: Bio-blots. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4045–4049. doi: 10.1073/pnas.80.13.4045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  28. Mecocci P., Cherubini A., Bregnocchi M., Chionne F., Cecchetti R., Lowenthal D. T., Senin U. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis Assoc Disord. 1998 Sep;12(3):211–214. doi: 10.1097/00002093-199809000-00015. [DOI] [PubMed] [Google Scholar]
  29. Mercken M., Vandermeeren M., Lübke U., Six J., Boons J., Van de Voorde A., Martin J. J., Gheuens J. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992;84(3):265–272. doi: 10.1007/BF00227819. [DOI] [PubMed] [Google Scholar]
  30. Mercken M., Vandermeeren M., Lübke U., Six J., Boons J., Vanmechelen E., Van de Voorde A., Gheuens J. Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. J Neurochem. 1992 Feb;58(2):548–553. doi: 10.1111/j.1471-4159.1992.tb09754.x. [DOI] [PubMed] [Google Scholar]
  31. Molina J. A., Benito-León J., Jiménez-Jiménez F. J., Ortí-Pareja M., Berbel A., Tallón-Barranco A., de Bustos F., Hernánz A. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Neurosci Lett. 1997 Dec 5;238(3):139–141. doi: 10.1016/s0304-3940(97)00858-6. [DOI] [PubMed] [Google Scholar]
  32. Mori H., Hosoda K., Matsubara E., Nakamoto T., Furiya Y., Endoh R., Usami M., Shoji M., Maruyama S., Hirai S. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett. 1995 Feb 17;186(2-3):181–183. doi: 10.1016/0304-3940(95)11291-4. [DOI] [PubMed] [Google Scholar]
  33. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995 Oct;38(4):643–648. doi: 10.1002/ana.410380413. [DOI] [PubMed] [Google Scholar]
  34. Oyama F., Shimada H., Oyama R., Titani K., Ihara Y. Differential expression of beta amyloid protein precursor (APP) and tau mRNA in the aged human brain: individual variability and correlation between APP-751 and four-repeat tau. J Neuropathol Exp Neurol. 1991 Sep;50(5):560–578. doi: 10.1097/00005072-199109000-00004. [DOI] [PubMed] [Google Scholar]
  35. Sjögren M., Minthon L., Davidsson P., Granérus A-K, Clarberg A., Vanderstichele H., Vanmechelen E., Wallin A., Blennow K. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) 2000;107(5):563–579. doi: 10.1007/s007020070079. [DOI] [PubMed] [Google Scholar]
  36. Sjögren M., Wallin A., Edman A. Symptomatological characteristics distinguish between frontotemporal dementia and vascular dementia with a dominant frontal lobe syndrome. Int J Geriatr Psychiatry. 1997 Jun;12(6):656–661. [PubMed] [Google Scholar]
  37. Skoog I., Vanmechelen E., Andreasson L. A., Palmertz B., Davidsson P., Hesse C., Blennow K. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration. 1995 Dec;4(4):433–442. doi: 10.1006/neur.1995.0052. [DOI] [PubMed] [Google Scholar]
  38. Spillantini M. G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998 Oct;21(10):428–433. doi: 10.1016/s0166-2236(98)01337-x. [DOI] [PubMed] [Google Scholar]
  39. Tibbling G., Link H., Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977 Sep;37(5):385–390. doi: 10.1080/00365517709091496. [DOI] [PubMed] [Google Scholar]
  40. Tullberg M., Månsson J. E., Fredman P., Lekman A., Blennow K., Ekman R., Rosengren L. E., Tisell M., Wikkelsø C. CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):74–81. doi: 10.1136/jnnp.69.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J. J., Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993 Nov;61(5):1828–1834. doi: 10.1111/j.1471-4159.1993.tb09823.x. [DOI] [PubMed] [Google Scholar]
  42. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjögren M., Andreasen N., Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000 May 5;285(1):49–52. doi: 10.1016/s0304-3940(00)01036-3. [DOI] [PubMed] [Google Scholar]
  43. Vermersch P., Bordet R., Ledoze F., Ruchoux M. M., Chapon F., Thomas P., Destée A., Lechevallier B., Delacourte A. Mise en évidence d'un profil particulier de protéines Tau pathologiques dans les cas de démences fronto-temporales. C R Acad Sci III. 1995 Apr;318(4):439–445. [PubMed] [Google Scholar]
  44. Vigo-Pelfrey C., Seubert P., Barbour R., Blomquist C., Lee M., Lee D., Coria F., Chang L., Miller B., Lieberburg I. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 1995 Apr;45(4):788–793. doi: 10.1212/wnl.45.4.788. [DOI] [PubMed] [Google Scholar]
  45. Wolozin B., Davies P. Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol. 1987 Oct;22(4):521–526. doi: 10.1002/ana.410220412. [DOI] [PubMed] [Google Scholar]
  46. Zemlan F. P., Rosenberg W. S., Luebbe P. A., Campbell T. A., Dean G. E., Weiner N. E., Cohen J. A., Rudick R. A., Woo D. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem. 1999 Feb;72(2):741–750. doi: 10.1046/j.1471-4159.1999.0720741.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES